Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3

Active, not recruiting

• Conditions: Melanoma; CNS-Spinal CD/MEMBR, NOS; Soft Tissue; Sarcoma; Lymph Nodes; Ovarian Cancer; Bone
• Interventions: Radiation: IGIMRT using a single dose of 24 Gy; Radiation: IGIMRT 27 Gy in 3 fractions

• Registration Number: NCT01223248
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to find out which way of giving high-dose radiation works best for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. This study will look at the effects, good and/or bad, of giving 27 Gy in three fractions (3 days) or 24 Gy in one fraction (1 day) using image-guided intensity-modulated radiotherapy (IG-IMRT). IG-IMRT is radiation that is given directly to the cancer site and reduces the exposure to normal tissue. Currently there are no studies that compare the effects of giving radiation in either hypofractionated doses (higher total doses of radiation spread out over several treatment days) or a single-fraction dose (entire radiation dose given in one treatment session).

The patient may be asked to participate in an additional part of this study where we will get a a (DW/DCE) MRI before treatment start and within one hour after radiation treatment. If the patient is asked to take part in this portion of the study, all they will need to do is get up to 3 MRIs with standard contrast injection. The purpose of this is to see if as a result of the treatment there are changes in the blood flow going to the cancer which could suggest that the treatment may be successful.

In addition some patients can present new lesions and may be asked if they would like to have these new lesions treated on the protocol. If they are given this option, this will not extend their follow up period. The follow up of the new lesions will match with the prior follow up dates.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10
• Study First Submitted: 2010-10-14
• Study First Submitted QC: 2010-10-14
• Study First Posted: 2010-10-18
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-01
• Last Update Posted: 2024-11-04
• Primary Completion: 2025-10
• Study Completion: 2025-10

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• Histologically or cytologically confirmed diagnosis of cancer (including epithelial carcinoma, sarcoma, and melanoma) The diagnosis can be done at MSKCC or at participating institutions.
• Sites of metastatic disease to be treated on protocol are limited to bone, spine, soft tissue, and lymph nodes only.
• Patients with American Joint Committee on Cancer (6th edition, 2002) Stage IV cancer with distant metastases
• Age 18 years or older
• Life expectancy >3 months
• Maximum tumor dimension of ≤6 cm in lymph nodes, soft tissue, osseous metastases, or spinal metastases seen on imaging (computed tomography [CT], magnetic resonance imaging [MRI], or PET/CT) and considered amenable for RT.
• If the lesion(s) to be treated are soft-tissue or lymph Nodes unidimensionally measurable disease is required. Bone & spine lesions are eligible even if considered non-measurable.
• Measurable disease is defined as:
• ≥ 10mm for soft-tissue lesions
• ≥ 15mm on the short axis of lymph nodes
• KPS ≥ 80
• Patients must have normal bone marrow function as defined below:(within 2 months of registration) Hemoglobin ≥9.0 g/dl Absolute neutrophil count (ANC) ≥1,500/μl Platelets ≥100,000/μl

Read More

Exclusion Criteria

• Prior radiotherapy delivered to the target region

• Disease to be treated on protocol is less than 2 mm from the spinal cord and therefore will not meet dose constraints*

• Pregnancy or Breast-Feeding (Participants of child-bearing potential are eligible but must consent to using effective contraception during therapy and for at least 3 months after completing therapy).

• Chemotherapy given on the day of the planned radiotherapy treatment

• Lesions which comprise >70% of the width of weight bearing bones, such as the femur.

• Existing cortical bone destruction, where orthopedic stabilization would be required.

• Areas to be treated on protocol do not include metastases to liver, brain or lung.

  • Note: Patients with eligible and ineligible lesions will be accrued to this protocol. Only target eligible lesions will be treated per protocol. Other eligible and ineligible lesions will be treated at the discretion of the treating physician."

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
stereotactic IGIMRT using a single dose of 24 Gy	IGIMRT using a single dose of 24 Gy	This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
stereotactic IGIMRT 27 Gy in 3 fractions	IGIMRT 27 Gy in 3 fractions	This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease

Primary Outcome Measures

Name	Time	Method
To compare the loco-regional control rates of two established hypo-fractionated radiation treatment regimens	2 years	a single dose of 24 Gy versus 27 Gy in three fractions for patients with metastatic disease

Secondary Outcome Measures

Name	Time	Method
To compare toxicity outcomes	2 years
To compare patterns of failure between these two cohorts.	2 years
To look at changes in SUV uptake as a measure of tumor response.	2 years	For patients who are followed with PET/CTs
changes in tumor perfusion	2 years	resulting from high-dose IGRT for patients treated with this approach to focal metastases using dynamic contrast-enhanced (DCE)-MRI.

Trial Locations

Locations (4)

University of California San Francisco; 🇺🇸 San Francisco, California, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

University of Pisa; 🇮🇹 Pisa, Italy

The Champalimaud Centre; 🇵🇹 Lisbon, Portugal